How eavesdropping on sexual signals helps young male crickets

Washington, May 13 (ANI): Sexual signals do more than just attract mates – in the case of crickets, says a new study.

Adult male crickets produce loud song to lure females, but the song can be overheard also by unintended receivers – such as young males unable to produce song due to a mutation they carry.

So far, researchers have not understood how non-singing male crickets use the song of singing males to modify their behavior or physical attributes to their advantage. Now, researchers at the University of California, Riverside have shed light on this mystery.

As part of the research, the scientists exposed one set of juvenile male crickets to a silent environment (which mimicked a population without very many singing males) and a second set of young male crickets to a song-rich environment (mimicking a population that contained lots of singing males).

Comparing the two sets of data, they found that male crickets growing up in the presence of abundant male song tend to be larger than male crickets growing up in a silent environment, and invest nearly 10 percent more reproductive tissue mass in their testes.

The researchers also found that male crickets that do not hear song during rearing are more likely to act as ”satellites,” hanging out near singing males and intercepting females on their way for matings.

“Subtle modifications of behavior depending on the environment, not genes, means that even in insects, animals aren”t ”programmed” or ”hard-wired” to do what they do,” said Marlene Zuk, a professor of biology, whose lab conducted the research.

Nathan Bailey, the lead author of the research paper, said: “Larger is probably better for the crickets because it allows males to better compete against other males in their environment. Being flexible according to who is around can be beneficial and help maximize the chance of reproducing.”

The new research suggests that sexual signals may play a hitherto under-appreciated role in determining how an animal looks and behaves once it grows up.

“Sexual signals do more than just attract mates. They can also influence other animals” development just by virtue of being perceived. The ability to change oneself according to the prevailing social conditions might be adaptive, especially in an environment that is constantly changing,” Bailey explained.

“On a more global scale, people often think of insects, especially the non-social insects, as mindless automatons, pre-programmed to carry out simple procedures throughout their lives.

“Our research shows quite the opposite, and demonstrates how even small, inconspicuous animals respond to the vagaries of their social environment by capitalizing on conspicuous signals that are intended for a different receiver,” Bailey added.

The study results appeared May 11 in the journal Current Biology. (ANI)

Two new genes linked to autism

Washington, May 3 (ANI): Scientists have identified two additional genes that may be associated with autism.

Study co-author Ning Lei, a researcher at Princeton University and the Institute for Advanced Studies, said that there is no known cause of autism, but mutations of several genes have been linked to autism.

For the study, Dr. Lei and her colleagues analyzed data from the Autism Genetic Resource Exchange (AGRE) on 943 families, most of whom had more than one child diagnosed with autism and had undergone genetic testing.

The researchers compared the prevalence of 25 gene mutations in the AGRE families with a control group of 6,317 individuals without developmental or neuropsychiatric illness.

The researchers identified mutations in four genes within the AGRE families. Two of the genes previously were shown to be associated with autism and often are involved in forming or maintaining neural synapses — the point of connection between individual neurons.

One of the new genes identified was neural cell adhesion molecule 2 (NCAM2). NCAM2 is expressed in the hippocampus of the human brain — a region previously associated with autism.

“While mutations in the NCAM2 gene were found in a small percentage of the children that we studied, it is fascinating that this finding continues a consistent story — that many of the genes associated with autism are involved with formation or function of the neural synapse. Studies such as this provide evidence that autism is a genetically based disease that affects neural connectivity,” Dr. Lei said.

The researchers hypothesize that a substantial percentage of children with autism will be shown to have a mutation in one or more of the many genes necessary for normal function of the synapse.

The study also showed that some parents and siblings of children with autism have the NCAM2 mutation but do not have the disorder themselves.

This suggests that other environmental or genetic factors are involved in causing autism in susceptible individuals.

“These results help the public understand that autism is a very complex disorder, much like cancer and no single gene or gene environment is likely to be causative in most cases,” Dr. Lei said.

The findings have been presented at the Pediatric Academic Societies (PAS) annual meeting in Vancouver, British Columbia, Canada. (ANI)

Vitamin, calcium supplements ‘can reduce breast cancer risk’

Washington, April 19 (ANI): A new study has suggested that vitamins and calcium supplements can reduce the risk of breast cancer.

The supplements are thought to help cells repair damaged DNA using a process that involves more than 200 proteins.

“It is not an immediate effect. You don”t take a vitamin today and your breast cancer risk is reduced tomorrow. However, we did see a long-term effect in terms of breast cancer reduction,” said Jaime Matta, professor in the Ponce School of Medicine in Puerto Rico.

“This process involves at least five separate pathways and is critical for maintaining genomic stability. When the DNA is not repaired, it leads to mutation that leads to cancer,” Matta added.

The study included 268 women with breast cancer and 457 healthy controls. Women were more likely to have breast cancer if they were older, had a family history of breast cancer, had no history of breastfeeding and had lower DNA repair capacity.

Vitamin supplements appeared to reduce the risk of breast cancer by about 30 percent. Calcium supplements reduced the risk of breast cancer by 40 percent.

After controlling for the level of DNA repair capacity, calcium supplements were no longer as protective, but the link between vitamin supplements and breast cancer reduction remained.

“We”re not talking about mega doses of these vitamins and calcium supplements, so this is definitely one way to reduce risk,” said Matta.

The study was presented at the American Association for Cancer Research 101st Annual Meeting 2010. (ANI)

Vitamin, calcium supplements ‘can reduce breast cancer risk’

Washington, April 19 (ANI): A new study has suggested that vitamins and calcium supplements can reduce the risk of breast cancer.

The supplements are thought to help cells repair damaged DNA using a process that involves more than 200 proteins.

“It is not an immediate effect. You don”t take a vitamin today and your breast cancer risk is reduced tomorrow. However, we did see a long-term effect in terms of breast cancer reduction,” said Jaime Matta, professor in the Ponce School of Medicine in Puerto Rico.

“This process involves at least five separate pathways and is critical for maintaining genomic stability. When the DNA is not repaired, it leads to mutation that leads to cancer,” Matta added.

The study included 268 women with breast cancer and 457 healthy controls. Women were more likely to have breast cancer if they were older, had a family history of breast cancer, had no history of breastfeeding and had lower DNA repair capacity.

Vitamin supplements appeared to reduce the risk of breast cancer by about 30 percent. Calcium supplements reduced the risk of breast cancer by 40 percent.

After controlling for the level of DNA repair capacity, calcium supplements were no longer as protective, but the link between vitamin supplements and breast cancer reduction remained.

“We”re not talking about mega doses of these vitamins and calcium supplements, so this is definitely one way to reduce risk,” said Matta.

The study was presented at the American Association for Cancer Research 101st Annual Meeting 2010. (ANI)

HIV uses several routes to escape immune system pressure

Washington, September 19 (ANI): Researchers at the Emory Vaccine Center have shown that HIV relies upon a number of strategies rather than use any preferred escape route to escape immune system pressure.

The human immune system has the ability to temporarily overpower HIV in early infection.

Studies conducted in the recent past have shown that most newly infected patients develop neutralizing antibodies. These are blood proteins that glob onto the virus and would allow patients to defend themselves – if they were facing only one target.

However, the problem occurs when HIV mutates, and disguises itself enough to get away from the antibodies. The virus eventually wears down the immune system into exhaustion.

The Emory team’s findings attain significance as they suggest that even if any scientist succeeds in identifying a vaccine component that can stimulate neutralizing antibodies, HIV’s capacity for rapid mutation could still be a confounding factor.

Dr. Cynthia Derdeyn, associate professor of pathology at Emory University School of Medicine, Emory Vaccine Center and Yerkes National Primate Research Center, says that a single type of neutralizing antibody may not be enough to contain HIV.

“These neutralizing antibodies work really well – they hit the virus fast and hard. But so far, every time we look, the virus escapes,” she says.

During the study, the researchers took blood samples from the participants a few weeks after infection occurred, and then later as two participants’ immune responses continued.

They isolated individual viruses over the first two years of HIV infection, and tested how well the patients’ own antibodies could neutralize them.

“In one patient where we had very early samples, there was evidence that neutralizing antibody came up within weeks, and that’s earlier than what was previously thought,” Derdeyn says.

In both patients, some viruses mutated part of their outer proteins so that after the mutation, an enzyme would be likely to attach a sugar molecule to it.

Though the sugar molecule interferes with antibody attack, this tactic, known as the “glycan shield”, was not observed in all cases.

Other viruses mutated the part of the outer protein that the neutralizing antibodies stick to directly. In both patients, many changes in the virus’ genetic code were necessary for escape.

“We need to understand early events in the immune response if we are going to figure out what a potential vaccine should have in it. What we can show is that even in one patient, several escape strategies are going on,” Derdeyn says.

According to her, that means that in order to be immune to HIV infection, someone may need to have several types of neutralizing antibodies ready to go.

Seeing how the virus mutates will allow researchers to choose the best parts to put in a vaccine, she says.

The results are online and scheduled for publication in the September issue of the journal Public Library of Science Pathogens.(ANI)

Turning off oncogene may inhibit lung cancer stem cells’ growth

Washington, Sep 9 (ANI): A lung cancer oncogene, called PKCiota, is necessary for the proliferation of lung cancer stem cells, and turning it off could act as a key for the treatment of this deadly disease, according to scientists at the Mayo Clinic campus in Florida.

These stem cells are rare and powerful master cells that manufacture the other cells that make up lung tumours, and are resistant to chemotherapy treatment.

The study also shows that an agent, aurothiomalate, being tested at Mayo Clinic in a phase I clinical trial substantially inhibits growth of these cancer stem cells.

“Our data indicate that PKCiota is required for the earliest steps in the development of lung cancer, which is the expansion of tumor-initiating cells or cancer stem cells,” said the study’s senior author, Dr. Alan Fields.

“Lung cancer stem cells appear to be the major drivers in many common lung cancers, and in order for a therapeutic treatment to be effective, it has to disrupt these cancer stem cells. We show that aurothiomalate, the agent now being tested in lung cancer patients, can, in fact, target these cells,” he added.

While aurothiomalate was once used to treat rheumatoid arthritis, the researchers have now discovered that it can also target PKCiota.

Currently, the agent is being tested in patients at Mayo Clinic’s sites in Minnesota and Arizona and, based on this phase I trial, a phase II human clinical trial is planned to combine aurothiomalate with agents targeted at other molecules involved in cancer growth.

“We had previously shown that PKCiota is required to maintain tumor growth, but what this study sought to determine is whether PKCiota is involved in the initial steps of lung cancer development,” said Fields.

Fields said that, in mice, an oncogene known as Kras is thought to transform normal lung stem cells into cancer stem cells, thereby initiating lung cancer.

In the present study, the researchers established a strain of mice in which Kras can be activated at the same time that the PKCiota gene is inactivated.

They found that when the PKCiota gene is inactivated, Kras was unable to cause errant growth and expansion of lung stem cells in mice, the process that initiates tumour formation.

“What this told us is that Kras requires PKCiota to transform the lung stem cells and make them proliferate. In other words, PKCiota is downstream from Kras, and is necessary for Kras to initiate lung tumor formation,” said Fields.

After discovering that aurothiomalate disables PKCiota, the researchers tested whether this agent is effective against lung cancer that develops due to Kras mutation.

“The drug showed potent inhibitory effects on the Kras-dependent proliferation of lung cancer stem cells both in cell culture and in animals,” said Fields.

“That further suggests that a drug like aurothiomalate could have an effect on tumors that are dependent on either Kras or PKCiota for growth and survival, and that is potentially a lot of cancers.

Aurothiomalate appears to be one of the few drugs available that can effectively target these critical cancer stem cells. In the clinic, however, it is likely that aurothiomalate will be most effective when combined with other agents designed to target other tumor survival pathways,” he added.

The study has been published in Cancer Research. (ANI)

Missing protein in rare genetic brain disorder restored

Washington, Sep 7 (ANI): By using protease inhibitors, researchers at the University of California-San Francisco (UCSF) have restored to normal levels a key protein that is involved in early brain development, and causes the rare brain disorder lissencephaly.

Reduced levels of the protein called LIS1 have been shown to cause lissencephaly, which is characterized by brain malformations, seizures, severe mental retardation and very early death in human infants.

The findings in mice offer a proof-of-principle that the genetic equivalent to human lissencephaly, also known as “smooth brain” disease, can be treated during pregnancy and effectively reversed to produce more normal offspring.

The researchers are hoping that this approach could also be used to treat other defects in utero, or even those manifesting after birth, when caused by a partial deficiency in one gene, according to Dr. Anthony Wynshaw-Boris.

“Researchers have not considered it possible to treat such a pervasive, early developmental brain disorder as lissencephaly. Not only were we able to show a clear cellular effect from using these protease inhibitors, but also were able to treat the disorder in utero,” Nature quoted Wynshaw-Boris as saying.

The work is the culmination of 15 years of collaborative research into the cause and mechanisms of lissencephaly, which is caused by a deletion or loss of one copy of the LIS1 gene, and affects an estimated one in 50,000-100,000 infants.

In 1998, the researchers reported of producing a mouse with the same mutation that displayed defective brain development.

The current research used these mice, and found that the protein calpain degrades the LIS1 protein to less than half its normal levels near the surface of the cells.

The team then used a specific small-molecule protease inhibitor of calpain in these mice.

At a cellular level, the protease inhibitors enabled LIS1 protein to be expressed at near-normal levels.

The team then gave daily injections of a calpain inhibitor to pregnant mice whose foetuses had the mouse-model of this defect.

They observed that the resulting offspring had more normal brains and showed no sign of mental retardation.

“This study is really a proof-of-principle not only for treating complex developmental brain disorders, but also for any disorder with reduced protein levels where proteases normally play some role in breaking down that protein. This will be much more difficult to apply to humans, because of the safety issues involved, but it could lead to new therapies that might be effective for a wide range of developmental disorders,” said the researchers.

The findings have been published in the journal Nature Medicine. (ANI)

New gene linked to progressive hearing loss identified

Washington, Sept 4(ANI): Scientists from The Scripps Research Institute have discovered a gene responsible for progressive hearing loss.

The has team found a gene, called Loxhd1, which is necessary for maintaining proper functioning hair cells in the inner ear.

However, mutations in this gene can lead to degradation of the hair cells and a disruption of the process that enables hearing.

“It is thought that mutations in several hundred genes can lead to deafness,” said team leader Ulrich Mueller, a professor in the Department of Cell Biology and member of the Skaggs Institute for Chemical Biology at Scripps Research.

“However, for many forms of deafness, we don’t know what effects the genes have. In this new research, we have linked a previously uncharacterized gene to deafness, first in mice and then in humans,” said Mueller.

During the study, researchers used a technique called forward genetics in their quest to better understand the genetic basis of hearing and hearing loss.

In forward genetics, scientists make mutations at random in germ cells, screen the resulting models for physical characteristics of interest (in this case hearing impairment), then amplify these traits through the breeding of several generations.

The gene responsible for the trait is then identified through positional cloning.

In this case, the scientists were able to generate a new mouse line with hearing impairment that they called samba and then clone the gene responsible, Loxhd1, which had never before been associated with deficits in hearing.

When the mice inherited two copies of the mutated gene, they were profoundly deaf shortly after birth.

This is the third hearing-related gene that the Mueller lab has discovered.

“In humans, the prevailing difficulty is progressive hearing loss,” he said.

“As you age, you lose your hearing slowly. Since this mutation can lead to progressive hearing loss, it provides us with more information on the genetic underpinnings of this condition and gives us clues as to how it might be corrected,” he added.

The study appears in American Journal of Human Genetics, a publication of Cell Press. (ANI)

Single gene behind essential tremor, Parkinson’s disease identified

Washington, September 2 (ANI): A single gene promotes development of essential tremor in some patients and Parkinson’s disease in others has been identified by an international team of researchers.

In a study report published in Parkinsonism and Related Disorders, Mayo Clinic researchers in Florida and their collaborators worldwide note that patients with essential tremor shake when they move, while those with Parkinson’s disease shake when they are at rest.

They further state that a variant in LINGO1, a gene involved in neuronal survival, is the first proven evidence of a common genetic component in the development of both disorders.

Analysing their findings, the researchers have come to the conclusion that mutations in this gene are potentially responsible for five percent of patients with Parkinson’s disease, and five percent of patients with essential tremor.

Lead researcher Dr. Carles Vilarino-Guell, of Mayo Clinic, said: “There is a mutation in the gene that must be causing or contributing to Parkinson’s disease in some people and essential tremor in others.”

He, however, added that that did not mean that people with essential tremor have an increased risk of developing Parkinson’s disease.

The findings are intriguing because “although essential tremor and Parkinson’s disease are considered to be different diseases, researchers have been arguing for a long time about whether essential tremor is a milder, preliminary form of Parkinson’s disease, and they have been looking for the genetic connection between these disorders,” he said.

“Now we know LINGO1 is the first gene identified,” he added.

The scientists have yet to identify any specific mutation or mutations on LINGO1 responsible for either disorder.

“The easiest explanation is that there are two separate and clearly distinct mutations in the gene contributing to the disorders. But because this gene doubles the risk of developing either disease and it is found at the same frequency in both diseases, it is possibly the same mutation,” Dr. Vilarino-Guell said.

“Both diseases are also affected by environmental factors, and that may influence which disorder a person would be more likely to develop,” he added. (ANI)

Regulation of ‘short stature’ gene crucial for growth in kids

Washington, August 26 (ANI): A team of researchers in Germany have found that not only a gene called SHOX is involved in the development of short stature, but sequences of genetic material on the X and Y chromosome that regulate it are also crucial for growth in children.

Professor Gudrun Rappold, the Director of the Department of Human Molecular Genetics at Heidelberg University Hospital, points out that these gene regulators determine how frequently a gene is copied, and, thus, how effective it is.

In many cases, she says, the mutation of one regulatory sequence of the SHOX gene is sufficient to give rise to the full-blown syndrome.

Publishing their results in the Journal of Medical Genetics, she and her colleagues have said that their findings may open up new possibilities for diagnosing the cause of short stature, and initiating treatment before it is too late.

According to background information in the report, the SHOX gene (short stature homeobox gene) is responsible for the normal growth of bones, and is often mutated in short-stature patients-no more than 160 cm of final height in men, and 150 cm in women.

Hormone disorders, malnutrition, chronic disease, or a genetic disorder are some of the causes of short stature. If, in addition to short stature, other symptoms such as short forearms and lower legs or other bone malformations also occur, it is considered a syndrome.

However, often no exact cause can be determined and other typical features are lacking – this is then known as idiopathic short stature.

In 2007, a research team led by Professor Rappold found that in over 4 percent of children with idiopathic short stature, the trigger for the disorder was a mutation in the SHOX gene. er latest study has shown that not only the gene itself, but its regulators as well can be crucial for developing the disease.

During the study, the researchers examined the genetic material from a total of 893 subjects.

About 5 percent of the patients with idiopathic short stature, and 80 percent of the patients with Leri-Weill syndrome, had mutations in the segment either including or around the SHOX gene.

The researchers said that some patients had an intact SHOX gene, but an unexpectedly high number of mutations in its enhancer sequences: for 26 percent of patients with SHOX deficiency and idiopathic short stature and for 45 percent of patients with SHOX deficiency and Leri-Weill syndrome, the disease could be attributed solely to a genetic mutation of the enhancer sequence.

“The astounding thing is that this enhancer mutation is quite far away from the affected gene and yet it still leads to the exact same clinical symptoms as a mutation in the gene itself,” said Professor Rappold.

The researchers hope that their results will give them a better understanding of the causes of the disease, and allow them to optimise the diagnostic possibilities for patients with SHOX gene mutations.

“Patients who suffer from their short stature often have a great need to be able to name the cause. Even if it is not possible to treat the cause, patients with mutations of the SHOX gene can benefit from a treatment of the symptoms with growth hormones,” said Professor Rappold. (ANI)

Clues to gigantism provided by family in Borneo Mountains

Washington, August 22 (ANI): An indigenous family living in a mountainous area of Malaysian Borneo has helped Van Andel Research Institute (VARI) scientists to discover information about genetic mutations associated with acromegaly, a form of gigantism that often results in enlarged hands, feet, and facial features.

The information could lead to better screening for the disease, which most often results from a benign pituitary gland tumor that can be deadly if left untreated, but which is difficult to detect until later stages when features become pronounced.

Researchers located a 31-member aboriginal family that included individuals with acromegaly living in a mountainous region of Borneo, Malaysia, when the effects of the family patriarch’s growing pituitary tumor necessitated medical treatment.

A medical team including VARI Distinguished Scientific Investigator Bin Tean Teh, and staff from the Department of Medicine at the University of Malaya Medical Centre and the Department of Medicine at the Queen Elizabeth Hospital in Malaysia subsequently traveled to the family’s village several times to collect blood samples for testing.

“Researchers had recently found a mutation in the AIP gene associated with acromegaly, but we found that several family members who didn’t have visible symptoms of acromegaly had this mutation as well,” said Dr. The.

“This increases the importance of screening for families with cases of acromegaly since anyone could be a carrier. On one side of the family, at least two generations carried the gene before someone showed any symptoms,” he added.

The later stages of acromegaly often produce enlarged hands and feet, protruding brows and lower jaws, thick voice and slowed speech from swelling of vocal cords, and other symptoms.

When diagnosed, the tumor and entire pituitary gland are usually removed, followed by hormone therapy for the rest of the patient’s life. owever, because the progression of the disease is so gradual, it is difficult to detect. If left unchecked, patients can die from complications such as heart or kidney failure.

Sok Kean Khoo, VARI Research Scientist and lead author of the study, led researchers in scanning DNA in the family’s blood to find other factors that might explain why only some family members with the genetic mutation had visible symptoms of the disease.

They found regions on a few chromosomes that might lead to further insight.The sooner we know how and why people are affected differently by this disease, the sooner we can help families who have it,” said Dr. Teh. (ANI)

Swine flu death rate estimates ‘flawed’

London, July 15 (ANI): The current estimates of the proportion of people who would die if infected with swine flu are flawed, according to researchers in UK.

Currently, it is estimated that the death rate owing to swine flu in the UK and the US is 0.5 per cent, which means that about five persons die for every 1000 people infected.

Thus, there is an urgent need for accurate estimates so that health authorities can best target treatment and vaccination strategies.

However, a new analysis has suggested three main reasons why current estimates may be wide of the mark.

The first and main source of uncertainty is the unknown number of infected people, who recover at home without notifying their doctors that they are ill, or receiving a diagnosis.

Thus, despite knowing how many patients are dying of swine flu in hospitals, doctors have no idea about what proportion of all cases are life threatening.

But they need both figures to work out the “case-fatality ratio”, which is calculated by dividing the number of fatal cases by the total number of cases.

“We don’t know the denominator,” New Scientist quited Azra Ghani, head of a team at Imperial College London tracking development of the epidemic in the UK as saying.

“For that reason, dividing the number of deaths by the number of cases may be flawed,” said Ghani’s colleague Tini Garske, the lead author of the study exposing gaps in the data.

The second piece of uncertainty is the possibility that deaths from swine flu are being attributed falsely to other causes of death, such as heart attacks or pneumonia from other causes.

This would lead to underestimates of the death rate.

And finally, statistics are distorted by a time lag between the point at which someone is infected and the time they die.

This could cause an apparent surge in deaths, which may falsely be interpreted as the virus becoming more deadly through mutation.

Taken together, these factors make it difficult to rely on existing data sources to accurately calculate the death rate or to predict the course of the epidemic.

However, Ghani has said that studies are already planned to rectify these shortcomings.

The study has been published in the British Medical Journal. (ANI)

Single gene mutation behind catastrophic epilepsy

Washington, July 8 (ANI): Researchers at Baylor College of Medicine have found a mutation in a single gene to be responsible for catastrophic epilepsy – characterized by severe muscle spasms, persistent seizures, mental retardation and sometimes autism.

Dr. Jeffrey Noebels, professor of neurology, neuroscience and molecular and human genetics at BCM and director of the Blue Bird Circle Developmental Neurogenetics Laboratory at BCM, said that the team replicated the defect in mice, developing a mouse model of the disease that could help researchers figure out effective treatments for and new approaches to curing the disease.

“While many genes underlying various forms of childhood epilepsy have been identified in the past decade, most cause a disorder of ‘pure’ seizures,” said Noebels.

Why some children have a more complicated set of disorders beginning with major motor spasms in infancy followed by cognitive dysfunction and developmental disorders such as autism remained a mystery until the discovery by the BCM team that a mutation in only a single gene explains all four features of catastrophic epilepsy.

A gene known as Aristaless-related homeobox or ARX has a specific mutation called a triplet repeat, which means that a particular genetic (in this case, GCG) is repeated many times in the gene.

When the researchers duplicated this particular mutation in specially bred mice, the animals had motor spasm similar to those seen in human infants.

Recordings of their brain waves showed that they had several kinds of seizes, included absence epilepsy and general convulsion. They also had learning disabilities and were four times more likely to avoid contact with other mice than their normal counterparts.

This behaviour is similar to that seen in children with autism or similar disorders in the same spectrum.

“The new model is an essential tool to find a cure for the disorder,” said Noebels.

The study appears in the current issue of the Journal of Neuroscience. (ANI)

Why H1N1 flu spreads from person to person less effectively than other flu viruses

Washington, July 3 (ANI): Scientists in the US have come up with an genetic explanation for why the new H1N1 “swine flu” virus has spread from person to person less effectively than other flu viruses.

A collaborative team of researchers from the Massachusetts Institute of Technology (MIT) and the Centers for Disease Control and Prevention have found that the H1N1 strain, which circled the globe this spring, has a form of surface protein that binds inefficiently to receptors found in the human respiratory tract.

“While the virus is able to bind human receptors, it clearly appears to be restricted,” says Ram Sasisekharan, the Edward Hood Taplin Professor and director of the Harvard-MIT Division of Health Sciences and Technology (HST) and the lead MIT author of the paper.

He points out that that restricted binding, along with a genetic variation in an H1N1 polymerase enzyme, which was first reported about three weeks ago in Nature Biotechnology, explains why the virus has not spread as efficiently as seasonal flu.

However, flu viruses are known to mutate rapidly, so there is cause for concern if H1N1 undergoes mutations that improve its binding affinity.

“We need to pay careful attention to the evolution of this virus,” says Sasisekharan.

For their study, the researchers compared the new H1N1 strain to several seasonal flu strains, including some milder H1N1 strains, and to the virus that caused the 1918 flu pandemic.

They found that the new strain is able to bind to the predominant receptors in the human respiratory tract, known as umbrella-shaped alpha 2-6 glycan receptors.

However, binding efficiency varies between flu strains, and that variation is partly determined by the receptor-binding site (RBS) within the hemagglutinin protein.

The researchers found that the new H1N1 strain’s RBS binds human receptors much less effectively than other flu viruses that infect humans.

They also observed that the new H1N1 strain spreads inefficiently in ferrets, which accurately mimics human influenza disease including how it spreads or transmits in humans.

When the ferrets were in close contact with each other, they were exposed to enough virus particles that infection spread easily. However, when they were kept separate and the virus could spread only through airborne respiratory droplets, the illness spread much less effectively.

Sasisekharan says that this is consistent with the transmission of this virus seen in humans so far, considering that most outbreaks have occurred in limited clusters, sometimes within a family or a school but not spread much further.

“One of the big payoffs of long-term investments in carbohydrate biology and chemistry research is an understanding of the relationships between cell surface carbohydrate structure and viral infectivity. Tools developed in building such understanding help in the response to events like the recent H1N1 outbreak,” said Jeremy M. Berg, director of the National Institute of General Medical Sciences of the National Institutes of Health, which partly funded the research.

The researchers also pinpointed a second mutation that impairs H1N1′s ability to spread rapidly.

While recent studies have shown that a viral RNA polymerase known as PB2 is critical for efficient influenza transmissibility, the new H1N1 strain does not have the version of the PB2 gene necessary for efficient transmission.

A research article describing the study has been published in the online edition of the journal Science. (ANI)

First case of Tamiflu resistance in pandemic swine flu emerges in Denmark

London, July 1 (ANI): For the first time, the National Health Board of Denmark has announced a case of pandemic H1N1 flu resistant to the antiviral drug Tamiflu.

However, the board has claimed, “there is no evidence” that the virus has spread.

While the case is likely to be isolated, the discovery has led to calls questioning the policy in most European countries of giving low doses of Tamiflu to people in contact with infected people.

The Danish case, a contact of someone who caught swine flu abroad, was given Tamiflu as prophylaxis to prevent her getting sick, but she still developed symptoms.

Later she took Relenza, another antiviral drug, and recovered.

The State Serum Institute in Copenhagen found that her virus carried a mutation giving resistance to Tamiflu.

Thus, they are thinking that the resistance emerged during treatment rather than having been there already.

“Such a development is no surprise from a scientific point of view,” New Scientist quoted David Reddy, head of the pandemic taskforce at Swiss company Roche, which produces Tamiflu.

Like antibiotics, antiviral drugs favour the survival of strains that resist the drug.

While Reddy said that the resistance in Danish case was unlikely to spread, but it is known that H1N1 viruses that resist Tamiflu are quite capable of spreading.

Already, the normal seasonal H1N1 virus became almost entirely Tamiflu resistant over the past two years.

Thus, scientists fear the pandemic virus, also a member of the H1N1 family, might acquire Tamiflu resistance by interbreeding with these ordinary strains.

It might also evolve resistance by exposure to the drug. (ANI)

Enzyme destroys mutated protein to cause inherited Parkinson’s disease

Washington, June 27 (ANI): Scientists have identified a naturally occurring enzyme in the brain, which helps in the destruction of the mutated protein that is the most common cause of inherited Parkinson’s disease.

Led by researchers at UT Southwestern Medical Center, the study used human cells and offered a focus for further research into halting the action of the mutated protein.

One of the most famous carriers of the mutation is Google co-founder Sergey Brin, who wrote about it on his blog in 2008.

Dr. Matthew Goldberg, assistant professor of Neurology and Psychiatry and senior author of the paper said: “There are currently enormous efforts to identify potential therapies based on inhibiting this mutated protein.”

He added: “Our paper is a major advance because we identify a protein that binds to the mutated protein and promotes its breakdown.”

The particular mutation examined in the study affects a protein whose function is not well understood, but in its normal form, it appears to have multiple sites where other molecules can attach themselves, like a space station with many docking areas.

Named LRRK2, the protein is vulnerable to several mutations, some of which can cause Parkinson’s disease.

For the study, the researchers used cultured human kidney cells and found that LRRK2 and a protein called CHIP “robustly” associated with each other.

On further testing, it was found that CHIP and LRRK2 could bind to each other in two different ways, either directly or indirectly by a third molecule that acted as a bridge.

The researchers observed that when CHIP bound to either the normal or mutant form of LRRK2, levels of LRRK2 in the cell decreased. This occurred because the cells increased the rate at which they destroyed LRRK2.

“CHIP may be a useful therapeutic target for treatments to break down LRRK2 in people with Parkinson’s,” said Goldberg.

He added: “Our next step is to identify cellular mechanisms that signal LRRK2 to be degraded by CHIP or by other mechanisms. Because LRRK2 mutations are believed to cause Parkinsonism by increasing the activity of LRRK2, enhancing the normal mechanisms that target LRRK2 for degradation by CHIP may be therapeutically beneficial.”

The study has been published in the journal Public Library of Science. (ANI)

‘Space Age’ cancer drug shows promise

London, June 25 (ANI): A new drug has shown promise in providing protection to individuals who were genetically vulnerable to developing cancers, say British researchers.

People carrying BRCA1 or BRCA2 mutations are an increased risk of developing cancer. It weakens the ability of a person’s cells to repair themselves.

While the risk of developing prostate cancer in men doubles from 7pct to more than 15pct, women’s chances of getting ovarian cancer increases from 2pct to 60pct.

Their chances of getting breast cancer also leaps from 10pct, to as much as 85pct.

The new drug called Olaparib – developed by the Institute of Cancer Research (ICR) in collaboration with The Royal Marsden Hospital and AstraZeneca – has been found to prevent malignant cells from repairing themselves.

Through this study, the researchers say, they have found a novel way of exploiting a fault inherent in BRCA mutation cancer cells to destroy them.

“By giving this drug we have made what has been an advantage to the cell in fact an achilles heel,” Sky News quoted Dr Johann de Bono, of the Institute of Cancer Research (ICR) as saying.

“This is really the holy grail of cancer treatment – selectively killing cancer cells and sparing normal cells,” de Bono added.

Traditional cancer treatments, like chemotherapy, kill both healthy and cancerous cells, however, Olaparib leaves healthy cells untouched. (ANI)

‘DNA Sudoku’ to revolutionise genome sequencing, medical genetics

Washington, June 25 (ANI): Sudoku, the popular mathematics puzzle that has taken people by storm, is now set to revolutionize the world of genome sequencing and the field of medical genetics, according to a new study.

Researchers at Cold Spring Harbor Laboratory (CSHL) have combined 2,000-year-old Chinese math theorem with concepts from cryptologyto develop what they dubbed as the “DNA Sudoku”, because of its similarity to the logic and combinatorial number-placement rules used in the popular game.

The strategy allows tens of thousands of DNA samples to be combined, and their sequences – the order in which the letters of the DNA alphabet (A, T, G, and C) line up in the genome – to be determined all at once.

The accomplishment is quiet contrary to past approaches that allowed only a single DNA sample to be sequenced at a time.

It also has an upper hand on current approaches that, at best, can combine hundreds of samples for sequencing.

“In theory, it is possible to use the Sudoku method to sequence more than a hundred thousand DNA samples,” said CSHL Professor Gregory Hannon, leader of the team that invented the “Sudoku” approach.

With such efficiency, the approach promises to reduce costs dramatically.

The new method has tremendous potential for clinical applications. It can be used, for example to analyse specific regions of the genomes of a large population and identify individuals who carry mutations that cause genetic diseases – a process known as genotyping.

The key to the team’s innovation is the pooling strategy, which is based on the 2,000-year-old Chinese remainder theorem.

The method is currently best suited for genotype analyses that require only short segments of an individual’s genome to be sequenced to find out if the individual is carrying a certain variant of a gene or a rare mutation.

However, with the improvement in sequencing technologies and researchers gaining the ability to generate sequences for longer segments of the genome, Hannon envisions wider clinical applications for their method such as HLA typing, already an important diagnostic tool for autoimmune diseases, cancer, and for predicting the risk of organ transplantation.

The report will be published as the cover story in the July 1 issue of the journal Genome Research.(ANI)

Understanding plants’ immune system will help researchers build better crops

Washington, May 28 (ANI): Researchers at the University of Missouri, US, have identified important suppressors that negatively regulate the responses of the immune system in the plant species Arabidopsis thaliana, which would allow breeders to create better yielding crop plants.

“The immune system provides plants with strong protection from pathogens,” said Walter Gassmann, associate professor of plant sciences in the MU Christopher S. Bond Life Sciences Center and the College of Agriculture, Food and Natural Resources.

“However, this response has the potential to be highly deleterious to the plant and needs to be tightly controlled. Certain suppressors protect the plant from responding to harmless stimuli and from overreacting to pathogens. If there is a mutation in these suppressors, the immune system can actually do more damage than good,” he added.ne way that plants fight pathogens is through effector-triggered immunity (ETI), which relies on the detection of pathogen effector proteins (proteins that are deployed by pathogens to interfere with the plant immune system).

After the detection of a pathogen, specific proteins in the plant, known as resistance proteins, elicit an effective defense response.

The plants’ resistance proteins are regulated by suppressors to achieve minimal side effects to the plant while providing optimal responses to pathogens.

However, when the ETI is overly activated, it can cause stunted growth and poor seed production.n the study, MU researchers examined plants with genetic mutations that resulted in heightened plant immunity.

By examining this mutation, researchers were able to identify specific genetic components that may negatively regulate the immune system and thus contribute to an appropriate immune response.The general control of effector-triggered signaling is poorly understood,” Gassmann said.

“Better insight into the immune system response will allow us to develop plants with more durable safeguards against pathogens,” he added. (ANI)

Personalised cancer treatment comes closer to reality

London, May 18 (ANI): Researchers at the University of California, San Diego School of Medicine have announced the development of an efficient system for delivering siRNA into primary cells, which may one day lead to personalized cancer treatment.

“RNAi has an unbelievable potential to manage cancer and treat it,” Nature magazine quoted Dr. Steven Dowdy, Howard Hughes Medical Institute Investigator and professor of cellular and molecular medicine at UC San Diego School of Medicine, as saying .

“While there’s still a long way to go, we have successfully developed a technology that allows for siRNA drug delivery into the entire population of cells, both primary and tumor-causing, without being toxic to the cells,” he added.

The researcher has revealed that his study focussed on the potential for a small section of protein called peptide transduction domain (PTD), which has the ability to permeate cell membranes, as a delivery mechanism for getting siRNAs into cancer cells.

In their previous work, he and his colleagues had generated over 50 “fusion proteins” using PTDs linked to tumour-suppressor proteins.

“Simply adding the siRNAs to a PTD didn’t work, because siRNAs are highly negatively charged, while PTDs are positively charged, which results in aggregation with no cellular delivery,” Dowdy said.

He said that his team solved the problem by making a PTD fusion protein with a double-stranded RNA-binding domain, termed PTD-DRBD, which masks the siRNA’s negative charge.

According to him, this allows the resultant fusion protein to enter the cell and deliver the siRNA into the cytoplasm, where it specifically targets mRNAs from cancer-promoting genes and silences them.

With a view to testing the PTD-DRBD fusion protein’s ability to deliver siRNA, the researchers generated a human lung cancer reporter cell line. They used green and fluorescent protein and analysed the cells using flow cytometry analysis.

Their efforts enabled them to determine the magnitude of RNA inhibitory response and the percentage of cells undergoing this response.

They found that the entire cellular population underwent a maximum RNAi response. Similar results were obtained in primary cells and cancer cell lines.

“We were subsequently able to introduce gene silencing proteins into a large percentage of various cell types, including T cells, endothelial cells and human embryonic stem cells. Importantly, we observed no toxicity to the cells or innate immune responses, and a minimal number of transcriptional off-target changes,” said Dowdy.

The researchers are of the opinion that the RNAi methods can be continually tweaked to combat new mutations, a way to overcome a major problem associated with current cancer therapies.

“Such therapies can’t be used a second time if a cancer tumor returns, because the tumor has mutated the target gene to avoid the drug binding. But since the synthetic siRNA is designed to bind to a single mutation and only that mutation on the genome, it can be easily and rapidly changed while maintaining the delivery system – the PTD-DRBD fusion protein,” said Dowdy. Cancer is a complex, genetic disease that is different in every patient. This is still in early stages, but I believe the siRNA-induced RNAi approach to personalized cancer treatment is the only thing on the table,” Dowdy added.

The study has been published in the advance on-line edition of the journal Nature Biotechnology. (ANI)